Skip to Main Content
Table 2

Numbers and rates of CVD events and MACE both overall and separately by preceding microvascular event status

Any CVD, n (rate*)MACE, n (rate*)
Overall 239 (6.1) 120 (3.0) 
Microvascular outcome   
 PDR (n = 360)   
  Yes 69 (14.1) 39 (7.4) 
  No 170 (5.0) 81 (2.3) 
 CSME (n = 413)   
  Yes 76 (13.0) 45 (7.2) 
  No 163 (4.9) 75 (2.2) 
 Three-step progression (n = 972)   
  Yes 150 (8.2) 82 (4.3) 
  No 89 (4.3) 38 (1.8) 
 PDR and/or CSME (n = 525)   
  Yes 99 (12.8) 58 (7.0) 
  No 140 (4.4) 62 (1.9) 
 AER ≥300 (n = 172)   
  Yes 39 (16.1) 27 (10.3) 
  No 200 (5.4) 93 (2.5) 
 Sustained AER ≥30 (n = 457)   
  Yes 103 (12.4) 57 (6.4) 
  No 136 (4.4) 63 (2.0) 
 eGFR <60 (n = 147)   
  Yes 31 (28.4) 20 (15.9) 
  No 208 (5.5) 100 (2.6) 
 Sustained AER ≥30 mg/24 h and/or eGFR <60 mL/min/1.73 m2 (n = 498)   
  Yes 110 (12.8) 60 (6.5) 
  No 129 (4.2) 60 (1.9) 
 CAN (n = 589)   
  Yes 99 (12.1) 57 (6.5) 
  No 140 (4.5) 63 (2.0) 
 Presence of retinal and kidney disease+   
  0 94 (3.5) 41 (1.5) 
  1 81 (9.1) 40 (4.3) 
  2 64 (17.1) 39 (9.6) 
Any CVD, n (rate*)MACE, n (rate*)
Overall 239 (6.1) 120 (3.0) 
Microvascular outcome   
 PDR (n = 360)   
  Yes 69 (14.1) 39 (7.4) 
  No 170 (5.0) 81 (2.3) 
 CSME (n = 413)   
  Yes 76 (13.0) 45 (7.2) 
  No 163 (4.9) 75 (2.2) 
 Three-step progression (n = 972)   
  Yes 150 (8.2) 82 (4.3) 
  No 89 (4.3) 38 (1.8) 
 PDR and/or CSME (n = 525)   
  Yes 99 (12.8) 58 (7.0) 
  No 140 (4.4) 62 (1.9) 
 AER ≥300 (n = 172)   
  Yes 39 (16.1) 27 (10.3) 
  No 200 (5.4) 93 (2.5) 
 Sustained AER ≥30 (n = 457)   
  Yes 103 (12.4) 57 (6.4) 
  No 136 (4.4) 63 (2.0) 
 eGFR <60 (n = 147)   
  Yes 31 (28.4) 20 (15.9) 
  No 208 (5.5) 100 (2.6) 
 Sustained AER ≥30 mg/24 h and/or eGFR <60 mL/min/1.73 m2 (n = 498)   
  Yes 110 (12.8) 60 (6.5) 
  No 129 (4.2) 60 (1.9) 
 CAN (n = 589)   
  Yes 99 (12.1) 57 (6.5) 
  No 140 (4.5) 63 (2.0) 
 Presence of retinal and kidney disease+   
  0 94 (3.5) 41 (1.5) 
  1 81 (9.1) 40 (4.3) 
  2 64 (17.1) 39 (9.6) 
*

Per 1,000 patient-years. +Presence of retinal and kidney disease is a quantitative variable defined as 0, no prior complications; 1, prior (PDR and/or CSME) or (severe albuminuria (AER ≥300 mg/24 h) and/or sustained eGFR <60 mL/min/1.73 m2) but not both; and 2, prior (PDR and/or CSME) and (severe albuminuria (AER ≥300 mg/24 h) and/or sustained eGFR <60 mL/min/1.73 m2).

Close Modal

or Create an Account

Close Modal
Close Modal